vTv Therapeutics
14
1
1
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
35.7%
5 terminated/withdrawn out of 14 trials
61.5%
-25.0% vs industry average
21%
3 trials in Phase 3/4
50%
4 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
Role: lead
Evaluation of TTP399 in Patients With Type 1 Diabetes
Role: lead
Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
Role: lead
2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)
Role: lead
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
Role: lead
Add Glucokinase Activator to Target A1c
Role: lead
A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes
Role: lead
A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes
Role: lead
A Safety Study of TTP4000 in Subjects With Alzheimer's Disease
Role: lead
A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes
Role: lead
TTP607 in Refractory Solid Malignancies
Role: collaborator
Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss
Role: lead
Left Ventricular Assist Device (LVAD) Specialized Centers of Clinically Orientated Research (SCCOR) Coagulation - Acute Intrinsic Pathway Antagonist (IPA)
Role: lead
Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)
Role: lead
All 14 trials loaded